Major Depressive Disorder

How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.

Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.

Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.

Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.

Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.

Pramipexole was associated with improvement in anhedonia and apathy, and with increased physical activity in patients with mood disorders, in a placebo-controlled trial that measured both behavioral and neurophysiologic change.

Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.

Much of what we call "treatment-resistant" depression may be mismatched, not resistant. A psychiatrist makes the case for trading the failed-drug tally for a difficult-to-treat framework clinicians can act on Monday morning.

Nardin Valetin, DO, explains how to spot hormonally driven mood symptoms in perimenopause and when HRT can support psychiatric treatment.

Explore why combining medication and psychotherapy often improves major depression outcomes, plus the latest debates on treatment sequencing and public trust in psychiatry.

HLP003, a deuterated psilocin agonist, enters phase 3 as an add-on for MDD, aiming to boost SSRI/SNRI response earlier.

Remote, home-based tDCS shows modest symptom relief and higher remission in major depression, with generally good safety but burn risks to watch.

From tricyclics to esketamine, Ron Pies, MD, explains antidepressant progress and why precise diagnosis matters when treating today’s diverse depression.

Experts weigh MDMA-like entactogens for social anxiety and depression, neuroplasticity windows, and what FDA setbacks mean for next-wave treatments.

Michael Thase, MD, explores evolving treatment strategies for treatment-resistant depression, including interventional psychiatry and emerging therapies.

Learn how clinicians tailor simple, measurable activity plans that boost depression and anxiety treatment—and improve long‑term adherence.

Learn how early antidepressant response guides faster treatment changes in major depression, with earlier use of esketamine, TMS, and ECT despite insurance barriers.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

Low-dose TNX-102 SL targets sleep receptors for MDD, avoiding norcyclobenzaprine buildup and promising cleaner daytime tolerability in HORIZON trial.

Explore how TNX-102 SL aims to improve major depressive disorder by enhancing slow-wave sleep, as the HORIZON phase 2 trial tests nightly dosing.

Explore next-gen depression therapies targeting neuroplasticity and why biomarkers may unlock precision psychiatry for MDD.

Concussion recovery in teen athletes often masks anxiety or depression; learn warning signs, screening tips, and safer return-to-play steps.

Meta-analysis ranks add-on atypical antipsychotics for MDD, comparing symptom response and dropout risks to guide smarter next-step treatment.

COMP360 psilocybin shows rapid, durable gains in treatment‑resistant depression, as psychedelics continue to grow.

Learn how fast-acting oral zuranolone treats postpartum depression in days, with practical prescribing and breastfeeding guidance clinicians can use.